ストックスクリーナーアプリを入手
1.97
0.51%
-0.01
前日終値:
$1.98
開ける：
$2.02
24時間の取引高:
149.50K
Relative Volume:
0.36
時価総額：
$89.13M
収益：
$8,000
当期純損益:
$-33.58M
株価収益率:
-2.3076
EPS:
-0.8537
ネットキャッシュフロー:
$-27.88M
1週間 パフォーマンス:
-18.60%
1か月 パフォーマンス:
-21.67%
6か月 パフォーマンス:
-21.83%
1年 パフォーマンス:
-74.45%
1日の値動き範囲:
$1.90
$2.07
1週間の範囲:
$1.96
$2.6121
52週間の値動き範囲:
$1.90
$8.535
Genelux Corp Stock (GNLX) Company Profile
名前
Genelux Corp
セクター
電話
805-267-9889
住所
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
1.97 | 89.13M | 8,000 | -33.58M | -27.88M | -0.8537 |
VRTX
Vertex Pharmaceuticals Inc
|
526.77 | 133.52B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
808.79 | 83.27B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
204.45 | 81.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
877.68 | 55.19B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.02 | 42.65B | 5.76B | 514.49M | 1.10B | 4.4813 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | Lake Street | Buy |
| 2024-10-29 | 開始されました | Guggenheim | Buy |
| 2024-08-28 | 開始されました | ROTH MKM | Buy |
| 2023-11-27 | 開始されました | H.C. Wainwright | Buy |
| 2023-09-12 | 開始されました | Maxim Group | Buy |
| 2023-02-15 | 開始されました | The Benchmark Company | Speculative Buy |
すべてを表示
Genelux Corp (GNLX) 最新ニュース
Genelux Corporation Common Stock (NASDAQ: GNLX) Stock Price, News & Analysis - kalkine.com.au
Genelux CorporationCommon Stock (Nasdaq:GNLX) Stock Quote - The Chronicle-Journal
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy - Yahoo Finance
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Genelux chief scientific officer Yu Yong sells $26,658 of stock By Investing.com - Investing.com South Africa
Genelux Corporation Common Stock (NASDAQ: GNLX) Stock Price, News & Analysis - kalkine.ca
Genelux chief scientific officer Yu Yong sells $26,658 of stock By Investing.com - Investing.com Canada
Genelux CTO Joseph Cappello sells $28,112 in company stock By Investing.com - Investing.com Nigeria
Genelux CEO Zindrick sells $91,899 in common stock - Investing.com India
Genelux CEO Zindrick sells $91,899 in common stock - Investing.com
Genelux CTO Joseph Cappello sells $28,112 in company stock - Investing.com
Genelux CTO Joseph Cappello sells $28,112 in company stock By Investing.com - Investing.com Canada
Genelux chief scientific officer Yu Yong sells $26,658 of stock By Investing.com - Investing.com UK
Genelux chief scientific officer Yu Yong sells $26,658 of stock - investing.com
Benchmark reiterates Genelux stock rating on cancer therapy progress - Investing.com
Benchmark reiterates Genelux stock rating on cancer therapy progress - Investing.com
Equities Analysts Offer Predictions for Genelux Q3 Earnings - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Auxly Cannabis Group (CBWTD), Genelux Corp. (GNLX) - The Globe and Mail
Genelux: Undervalued Oncolytic Virus Leader as Olvi-Vec Nears Key Phase 3 Ovarian Cancer Catalyst - TipRanks
Genelux (NASDAQ:GNLX) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Genelux Reports Second Quarter 2026 Results and Advances Olvi-Vec Clinical Programs in Ovarian and Lung Cancer - Quiver Quantitative
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates - Yahoo Finance
Genelux (NASDAQ:GNLX) Issues Earnings Results - MarketBeat
GENELUX Corp 6M 2026: Revenue $0 Net loss $(18.4M), EPS $(0.41) — 10-Q Summary - TradingView
Genelux (GNLX) deepens losses while funding Phase 3 cancer trial and warning on cash runway - Stock Titan
Genelux Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Genelux Corp (GNLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Genelux Corp (GNLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Genelux Corporation (GNLX) Slips 1.11% as Shares Test Support Near $2.54High Low Breadth - dars.gov.et
Insiders Sold Genelux At US$3.34, Meanwhile Stock Sits Near US$2.51 - Sahm
Genelux Corp expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Genelux (GNLX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Genelux Corp (GNLX) Balance Sheet - tradingkey.com
Genelux Corp (GNLX) Cash Flow - TradingKey
Genelux Corp (GNLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Genelux Corp (GNLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Genelux Corp (GNLX) Income Statement - TradingKey
GNLX|Genelux Corp|Price:2.890|Chg%:-0.070 - TradingKey
Genelux Corp (GNLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Genelux (NASDAQ:GNLX) Shares Down 2.4%Should You Sell? - marketbeat.com
Genelux Corp (GNLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider Shake-Up at Genelux Corp Sparks Investor Attention - TipRanks
GENELUX (NASDAQ: GNLX) director sells 12,000 shares to cover RSU tax bill - Stock Titan
[144] GENELUX Corp SEC Filing - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer - The Manila Times
Genelux says Olvi-Vec may reawaken platinum response in ovarian cancer - Stock Titan
Genelux Corp. Actuals & Estimates (NASDAQ:GNLX) - TradingView
Genelux Corporation 8-K Filing: Company Details, Nasdaq Listing, and Emerging Growth Status (June 2026) - Minichart
Genelux elects director and ratifies auditor at annual shareholder meeting - Investing.com
Genelux Corp (GNLX) 財務データ
収益
当期純利益
現金流量
EPS
Genelux Corp (GNLX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Yu Yong | Chief Scientific Officer |
Aug 31 '26 |
Sale |
2.75 |
9,683 |
26,658 |
258,688 |
| Zindrick Thomas | President and CEO |
Aug 31 '26 |
Sale |
2.67 |
34,463 |
91,899 |
1,226,427 |
| Cappello Joseph | Chief Technical Officer |
Aug 04 '26 |
Sale |
2.95 |
653 |
1,924 |
328,737 |
| Zindrick Thomas | President and CEO |
Aug 04 '26 |
Sale |
2.95 |
3,023 |
8,905 |
1,260,890 |
| Yu Yong | Chief Scientific Officer |
Aug 04 '26 |
Sale |
2.94 |
653 |
1,922 |
268,371 |
| JOHN SMITHER | Director |
Jul 01 '26 |
Proposed Sale |
2.91 |
12,000 |
34,898 |
0 |
| Smither John W | Director |
Jul 01 '26 |
Sale |
2.91 |
12,000 |
34,898 |
91,403 |
| Smalling Ralph | Head of Regulatory |
Jun 03 '26 |
Sale |
2.93 |
192 |
563 |
67,611 |
| JOHNNY THOMAS | Officer |
Jun 01 '26 |
Proposed Sale |
3.05 |
10,000 |
30,500 |
0 |
| Thomas John | Director |
Jun 01 '26 |
Sale |
2.98 |
10,000 |
29,801 |
472,784 |
7.00%
大文字化:
|
ボリューム (24 時間):